Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
RevSTAR-123
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
- NCT05949125 ↗
- Recruiting
- AvenCell Europe GmbH
- Focused
We haven't built an HCP commentary report on RevSTAR-123 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RevSTAR-123 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory
- Interventions
- Cyclophosphamide (Non-IMP, Lymphodepletion); Fludarabine (Non-IMP, Lymphodepletion); R-TM123; Allo-RevCAR01-T
- Arms
- Allo-RevCAR01-T-CD123 treatment · Experimental
- Enrollment
- 37 (estimated)
- Primary outcomes
- Safety and tolerability
- Sponsor
- AvenCell Europe GmbH with Allucent (NL) BV
- Start
- Jan 3, 2024
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05949125 · updated Sep 24, 2026